{"id":"W1982681524","doi":"10.1086/650342","title":"Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment‐Experienced Subjects: 48‐Week Results of the VICTOR‐E1 Phase 2 Trial","year":2010,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"National Institutes of Health; Universidade Estadual de Campinas; Universidade de São Paulo; Pontificia Universidade Catolica de Campinas; Department of Science and Technology, Ministry of Science and Technology, India; National Institute of Allergy and Infectious Diseases; Universität Zürich; University of Pittsburgh; McMaster University; Center for AIDS Research, University of Washington; University Health Network","keywords":"Placebo; Regimen; Medicine; Internal medicine; Ritonavir; Adverse effect; CCR5 receptor antagonist; Viral load; Clinical endpoint; Indinavir; Gastroenterology; Protease inhibitor (pharmacology); Randomized controlled trial; Clinical trial; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002296601,0.001287518,0.002109231,0.0002838658,0.0002288658,0.000820469,0.0007617387,0.001458408,0.004860717],"category_scores_gemma":[0.001280369,0.0004247704,0.001279241,0.0002380727,0.0005485759,0.0006716624,0.0002949956,0.00169456,0.0008927755],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004813479,"about_ca_system_score_gemma":0.000780572,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004037018,"about_ca_topic_score_gemma":0.0007502035,"domain_scores_codex":[0.999248,0.0004628268,0.00003304056,0.00009961383,0.00005321064,0.0001033317],"domain_scores_gemma":[0.9994196,0.0001344125,0.0001500278,0.00006123059,0.00004027854,0.0001945049],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9076341,0.01832789,0.001796909,0.0006793881,0.00127844,0.00009583691,0.0001051244,0.0008442472,0.01016442,0.0001596847,0.002012328,0.05690158],"study_design_scores_gemma":[0.8425931,0.1503321,0.004076947,0.00003356907,0.0003078026,0.00008703169,0.00001854132,0.0005488335,0.0006588206,0.00009441193,0.001231775,0.00001699038],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990752,0.004069147,0.0004872872,0.0003497165,0.0001149166,0.001417078,0.0008611028,0.0000936818,0.001854958],"genre_scores_gemma":[0.9858658,0.002801356,0.001741983,0.0009356612,0.0002567154,0.002933105,0.00204076,0.00003829047,0.003386384],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004860717,"threshold_uncertainty_score":0.01626074,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01603981379382488,"score_gpt":0.3052728313233687,"score_spread":0.2892330175295438,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}